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Abstract
Human disease is heterogeneous, with similar disease phenotypes resulting from distinct combinations of genetic and
environmental factors. Small-molecule profiling can address disease heterogeneity by evaluating the underlying biologic
state of individuals through non-invasive interrogation of plasma metabolite levels. We analyzed metabolite profiles from an
oral glucose tolerance test (OGTT) in 50 individuals, 25 with normal (NGT) and 25 with impaired glucose tolerance (IGT). Our
focus was to elucidate underlying biologic processes. Although we initially found little overlap between changed
metabolites and preconceived definitions of metabolic pathways, the use of unbiased network approaches identified
significant concerted changes. Specifically, we derived a metabolic network with edges drawn between reactant and
product nodes in individual reactions and between all substrates of individual enzymes and transporters. We searched for
‘‘active modules’’—regions of the metabolic network enriched for changes in metabolite levels. Active modules identified
relationships among changed metabolites and highlighted the importance of specific solute carriers in metabolite profiles.
Furthermore, hierarchical clustering and principal component analysis demonstrated that changed metabolites in OGTT
naturally grouped according to the activities of the System A and L amino acid transporters, the osmolyte carrier SLC6A12,
and the mitochondrial aspartate-glutamate transporter SLC25A13. Comparison between NGT and IGT groups supported
blunted glucose- and/or insulin-stimulated activities in the IGT group. Using unbiased pathway models, we offer evidence
supporting the important role of solute carriers in the physiologic response to glucose challenge and conclude that carrier
activities are reflected in individual metabolite profiles of perturbation experiments. Given the involvement of transporters
in human disease, metabolite profiling may contribute to improved disease classification via the interrogation of specific
transporter activities.
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Introduction
Disease heterogeneity has challenged the practice of medicine.
Individuals with the same apparent disease at our current
diagnostic resolution often show remarkable variation in prognosis
and treatment responsiveness, presumably because a superficially
similar disease state can arise from diverse combinations of genetic
and environmental factors [1]. Efforts to resolve the heterogeneity
have focused on collecting increasing amounts of quantitative
patient information, including genotypic [2] and mRNA [3] and
protein expression data [4] with the hope of establishing better
clinical classifiers based on aberrant activities of specific, targetable
biological pathways.
Using tumor biopsy samples, oncologists are now exploring the
incorporation of genomewide expression profiling into therapy
[5,6]. However, for complex human diseases that span multiple
organ systems, metabolomics—the analysis of a broad array of
metabolite levels from biologic fluid samples such as blood or
urine—represents a minimally-invasive way to obtain quantitative
biologic information from patients to uncover disease pathophys-
iology and aid diagnostic and prognostic classification [7].
Metabolomics data analysis may be facilitated by techniques
applied to other high-throughput ‘omic data types. For microarray
data, the integration of network information from protein-protein
interaction data or predefined biologic pathways has greatly assisted
elucidation of underlying processes and led to the development of
increasingly robust and accurate gene-based classifiers for disease
[8,9]. We hypothesize that the characterization of human disease by
metabolomic profiling should similarly benefit from interpreting
metabolite changes in the context of known metabolic reactions.
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We use data derived from oral glucose tolerance tests (OGTT) in
25 individuals with normal (NGT) and 25 with impaired (IGT)
glucose tolerance [10]. We first sought significant overlaps between
observed metabolite changes and preconceived definitions of
metabolic pathways. Next we applied an unbiased pathway analysis
by mapping the metabolite changes to a recent reconstruction of the
humanmetabolic network [11] and use a recently developed variant
[12] of previous approaches [13] derived for mRNA expression
analysis to find active metabolic modules—connected subnetworks
of highly changed metabolites. While the biased approach yielded
little, the resulting unbiased pathway models highlight the
interconnectedness between changed metabolites and propose a
role for solute carriers in OGTT metabolite profiles. Hierarchical
clustering and principal component analysis confirmed the
importance of specific transporters by demonstrating that metab-
olites cluster naturally according to activities of the System A and L
amino acid and SLC6A12 osmolyte transporters. Furthermore, they
suggest an important role for the SLC25A13 mitochondrial
aspartate-glutamate transporter in interindividual metabolite profile
variability. Comparison of NGT and IGT active modules suggest
blunted glucose- and/or insulin-stimulated enzyme and transporter
activities in the IGT group. Given that transporters are implicated
in multiple human diseases, the interrogation of transporter
activities by perturbation-based metabolic profiling may ultimately
contribute to improved disease classification and resolution of
disease heterogeneity.
Results
Predefined Pathways Show Little Enrichment for
Changed Metabolites
We examined metabolite profiles from a previously descibed
oral glucose tolerance experiment (OGTT) [10], which involved
the use of metabolite profiling to monitor physiologic responses
to oral glucose challenges in individuals with normal (NGT) and
impaired glucose tolerance (IGT). Multiple metabolites were
changed significantly in response to glucose in two separate NGT
populations. Furthermore, interpreting the list of changed meta-
bolites in terms of known mechanisms of insulin action allowed the
authors to assign the observed results to established biochemical
pathways, including glycolysis, lipolysis and ketogenesis, and led to
the proposal of new downstream pathways of insulin action, such
as bile acid metabolism [10]. Many of the changed metabolites
were not, however, mapped to established pathways.
We were thus interested in further elucidating the underlying
biologic processes leading to the observed pattern of changes.
Analyzing the OGTT metabolite profiles of the 25 NGT and 25
IGT Framingham Heart Study participants (see Methods), we
identified 57 and 31 metabolites, respectively, changed at an FDR
of 0.05 (see Table S1). We first revisited whether the pattern of
changed metabolites was consistent with predefined metabolic
pathways using the FuncAssociate program [14]. FuncAssociate
uses a hypergeometric test and correction for multiple hypothesis
testing to formally evaluate statistical significance for pathway
enrichment (see Methods). Although originally designed to identify
enriched ‘‘gene sets’’ among a list of genes, FuncAssociate can be
adapted for ‘‘metabolite sets’’. We used a recent reconstruction of
the human metabolome, ‘‘Recon 1’’, as a source of pathway
information [11]. The significantly changed metabolites were
ranked by magnitude of change and FuncAssociate was used to
identify significant enrichment of any of the 99 separate metabolic
pathways in Recon 1.
We evaluated NGT and IGT individually (comparing metab-
olite abundance before and after oral glucose load) and found
enrichment solely in NGT for Bile Acid Biosynthesis at an adjusted
p-value ,0.001.
Active Module Analysis Elucidates Metabolic Pathways of
OGTT
The low yield of pathway enrichment could arise in part from
the sparseness of our metabolome coverage or from the fact that
most metabolites are implicated in multiple pathways. Further-
more, even if a pathway has uniformly increased flux, this will not
generally lead to uniform increases in metabolite abundance. The
relationship between enzymatic activity and metabolite concen-
tration can be understood in terms of the relative contribution of
‘‘metabolic regulation’’ and ‘‘hierarchical regulation’’. Metabolic
regulation involves control of reaction flux through the interaction
of enzymes with the rest of the metabolic network, such as
changing substrate, product or modifier concentrations [15]. On
the other hand, hierarchical regulation achieves control through
changes in maximal enzyme activity, typically by altered gene
expression. In the extreme case where there is simultaneous and
proportional modulation of the activity of all enzymes in the
pathway, one would see no changes in metabolite concentrations
in a pathway despite changes in metabolic flux. A final explanation
for the low yield of enriched predefined pathways may be that the
physiologic perturbation only affects a subnetwork of metabolites
that may not correspond to any of the preconceived pathway
definitions. In light of these possibilities, we investigated the
application of additional, emerging bioinformatics approaches,
which emphasize unbiased pathway models.
We based our analysis on the fact that metabolites are linked via
chemical reactions. We hypothesized that OGTT is a physiologic
stimulus that alters flux through specific metabolic reactions. Since
products from one reaction may serve as reactants for and drive
other reactions, we sought groups of metabolites that are
connected through metabolic reactions and collectively show a
high degree of change. Furthermore we hypothesized that a
perturbation such as OGTT would increase the activity of
Author Summary
Human disease is complex, arising from the interaction of
many genetic and environmental factors. Efforts to
personalize treatment have been thwarted by ‘‘phenotypic
heterogeneity’’, the apparent similarity of disease states
with diverse underlying causes. One approach to resolve
this heterogeneity is to redefine diseases on the basis of
abnormal physiologic activities, which should allow
grouping patients into categories with similar treatment
response and prognosis. Physiologic activities can be
identified and assessed through quantitative measure-
ments of biomolecules—proteins, mRNAs, metabolites—in
individual patient samples. The field of metabolomics
involves the analysis of a broad array of metabolite levels
from clinical fluid samples such as blood or urine and can
be used to evaluate disease states. Because metabolic
profiles are complex, we have taken an integrative
network-based approach to understand them in terms of
abnormal activities of enzymes and small molecule
transporters. We have focused on the oral glucose
tolerance test, used to diagnose diabetes, and have found
that multiple transporters play an important role in the
normal response to ingesting sugar. Many of these
transporter activities are abnormal in individuals with
impaired glucose tolerance and differing activities among
them may reflect the diverse underlying causes and
variable clinical courses of such patients.
Unbiased Pathway Models in Metabolomics
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enzymes and transporters, many of which have multiple substrates.
Thus, we were also interested in groups of changed metabolites
linked by virtue of being substrates of a common enzyme or
transporter.
We framed the search for functionally-linked, highly changed
metabolites in OGTT in terms of the discovery of active modules (or
subnetworks). Active module approaches have previously been
applied in bioinformatics analysis to elucidate underlying biologic
processes in gene expression data. In such analyses, the investigators
typically overlaid gene scores based on differential expression in
microarray experiments onto protein-protein interaction [16,17]
and/or transcription-regulatory [13] networks and looked for
highly-connected, differentially expressed genes. We undertook a
similar approach, combining OGTT metabolite profiles with
metabolic reaction information.
We first built a Metabolic Reaction Network (MRN) using the
3338 metabolic reactions in Recon 1. Although Recon 1 includes
most known transport reactions, the specific transporters were not
always explicitly mentioned. Thus we expanded this list with 737
additional reactions explicitly modeling transport processes for the
metabolites measured in this experiment (see Methods, Table S2),
highlighting the relevant transporter for each reaction. We treated
all reactants and product metabolites as nodes. Cellular locations
were assigned to each metabolite as specified in Recon 1, and
metabolites were split into multiple nodes (each corresponding to a
different location). For example, five nodes in the MRN were
assigned to D-Glucose, corresponding to glucose in the cytoplasmic,
lysosomal, Golgi, endoplasmic reticulum and extracellular com-
partments. Edges were drawn between reactants and products in
chemical reactions (see Methods and Figure 1) and between all
substrates for each of the known enzymes or transporters catalyzing
metabolic reactions (Table S2). In effect, we proceeded from a
bipartite undirected graph [18], where both metabolites and pro-
teins (enzymes/transporters) are represented as nodes, and inter-
actions between metabolites and proteins represented as edges, to a
unipartite metabolite interaction graph, where metabolites that are
common substrates of enzymes or transporters were connected
by edges. For those reactions where enzymes/transporters are
Figure 1. Analysis flowchart for metabolic reaction network construction, active module discovery, and evaluation of active
module sets for enrichment for predefined biologic pathways, enzymes/transporters, and tissue activity.
doi:10.1371/journal.pcbi.1000692.g001
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unknown or unneeded, the corresponding reactant and product
metabolites were directly connected.
We converted experimental measures of significance of change
(p-values) for metabolites to scores (see Methods). Since Recon 1
includes cellular locations for reactions, if a metabolite had
multiple cellular locations, different active modules could emerge,
depending on the location to which a score was assigned. We
hypothesized that the plasma metabolite profiles of perturbation
experiments reflect altered flux in both intracellular reactions and
in metabolite transport between the cell and plasma. We focused
on each of these processes separately, building two scored MRNs.
In the first, the Scored Extracellular MRN (EMRN), we assigned
the score to the extracellular metabolite, modeling extracellular
levels as being reflected in plasma. We also built a separate Scored
Cytoplasmic MRN (CMRN), assigning the same scores to the
cytoplasmic metabolite to better capture interconnections via
intracellular reaction processes (we thus make the assumption that
extracellular transport is not limiting, and that plasma metabolite
abundance reflect intracellular abundances). We then looked for
active modules, which represent connected subnetworks with high
aggregate activity, using a recently published algorithm, developed
for mRNA expression analysis [12], to provide an exact solution.
We pursued active module searches for NGT and IGT, for both
the EMRN and CMRN. Since not all metabolites in the MRNs
were measured in the metabolomics experiment, we randomly
sampled scores for the remaining metabolites and computed 100
active module solutions for each of the scored MRNs (see
Methods, Figure 1).
Distributions of active module scores were evaluated for statistical
significance relative to those obtained from random networks,
where metabolite scores were permuted randomly amongst
measured nodes. At an FDR threshold of 0.01, all of the solutions
were highly significant (p=8.561028 for NGT-EMRN, 7.461029
for NGT-CMRN, p=7.0610215 for IGT-EMRN, p=0.025 for
IGT-CMRN, respectively, Mann-Whitney-Wilcoxon test) indicat-
ing that the clustering of metabolite changes in the network is highly
non-random.
Characterizing Active Modules of OGTT using
FuncAssociate.
We selected all metabolites that appeared with sufficient frequency
(see Methods) across the active module solutions. This resulted in an
Active Module Group (AMG) for each of NGT-EMRN, NGT-
CMRN, IGT-EMRN, and IGT-CMRN. Metabolite frequencies
for searches are shown in Table S3. As the AMGs represent
unbiased pathway models for the OGTT experiment, we sought to
characterize their relationship to predefined biological processes. We
first repeated the FuncAssociate analysis and found marginal
enrichment for Glycerophospholipid Metabolism (padj = 0.029) for
the NGT-EMRN AMG and more convincing enrichment for
Glycine, Serine, and Threonine Metabolism (padj = 0.008) within the
NGT-CMRN AMG. However, these enriched predefined pathways
encompass very few of the AMG metabolites.
We next sought to characterize whether the AMGmetabolites are
active in any particular human tissue. To do so, we exploited recent
predictions of which metabolic reactions in the Recon 1 network
were likely to be active in ten specific human tissues, using constraint-
based flux modeling [19]. We tested whether AMGs correspond to
predicted metabolic activities in any of these tissues (see Methods).
AMGs all showed enrichment (padj,0.05) for metabolites predicted
to be active in kidney and/or liver, suggest that OGTT responses
primarily involve metabolites produced in and/or consumed in these
organs. Both tissues are established targets of insulin action, with liver
demonstrating increased glycogen storage and fatty acid production
and decreased gluconeogenesis [20] and kidney showing changes in
electrolye clearance [21] in response to insulin.
Active Modules Suggest Amino Acid Transporters
Involved in Glucose Response
An inspection of the AMGs for NGT samples (Figure 2) revealed
a central cluster of highly interconnected standard (15) and
nonstandard amino acids (5), 19 of which decrease in plasma in
response to glucose challenge. (The AMGs for IGT samples (Figure
S1) consist entirely of standard (11) and non-standard amino acids
(2) and are discussed further below.) Standard amino acids represent
building blocks for proteins, whereas nonstandard amino acids such
as citrulline, ornithine, dimethylglycine and homoserine are
implicated in other biologic processes (see below). Within the
EMRN, all edges between amino acids correspond to shared
transporters, while within the CMRN, in addition to shared
transporter activity edges, some edges constitute reactant-product
pairs and/or shared enzyme substrates. The interconnectedness of
both standard and nonstandard changed amino acids in the AMG
supports the hypothesis that metabolite profiles reflect both
increased protein synthesis and altered amino acid transporter
activity. In fact, it is known that certain amino acid transporter
activities are activated in response to insulin (see below).
Amino acid transport activities have historically been grouped
into ‘‘Systems’’ that describe the chemical properties of the
transported molecules (e.g. cationic or small/neutral) and the
response to specific inhibitors [22]. Transporters can also be
classified by whether their transport activity is primarily effected
via facilitated diffusion or exchange reactions and also by the co-
transported ions (e.g. sodium, protons, potassium, or chloride).
Individual transporters, once cloned, have been mapped to these
Systems. We used FuncAssociate to identify which enzymatic
activities or transporters are overrepresented in the AMGs. Table 1
indicates enzymes or transporters with substrate profiles demon-
strating significant overlap with AMG metabolites in the
experiment. Transporters with broad amino acid specificity such
as the SLC6 and SLC7 families are favored in the FuncAssociate
enrichment analysis. However, given that many of these tran-
sporters have tissue-specific activities, there is probable involve-
ment of other transporter families in glucose-stimulated amino
acid influx, including the SLC38 (SNAT) family of small polar
amino acid transporters, and the SLC1 family of anionic amino
acid transporters. The SLC38A2 transporter, a weakly-accumu-
lating neutral amino acid transporter, is in fact known to be post-
translationally regulated by insulin in murine adipocyte [23] and
rat skeletal muscle cell lines [24]. Furthermore, insulin has been
shown to increase System A (small, neutral amino acid) and
System L (large hydrophobic) amino acid transport activities in
cultured trophoblasts [25]. A complete list of all possible
transporters and enzymes corresponding to the edges in the
AMGs is provided in Table S4.
Active Modules Identify the Interconnectedness of
Multiple Changed Metabolites
In addition to the core cluster of amino acids, the AMGs include
additional changed metabolites on their periphery. These
peripheral metabolites are connected to the amino acid core via
unmeasured metabolites, which represent potential functional
links. For example, in the NGT-CMRN AMG (Figure 2B),
glutamate is linked to nicotinamide and ribose-5-phosphate via the
unmeasured metabolite phosphoribosyldiphosphate (PRPP). Glu-
tamate and PRPP are a reactant-product pair and common
substrates of the enzyme glutamate-PRPP amidotransferase. In the
Unbiased Pathway Models in Metabolomics
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Figure 2. ActiveModule Groups from the NGT-EMRN andNGT-CMRN. Panels (a) and (b) correspond to NGT-EMRN and NGT-CMRN, respectively.
Nodes in the AMGs correspond to metabolites in chemical reactions and edges are drawn between reactant-product pairs or shared substrates of
enzymes/transporters. A gradient from gold to blue was used to denote reduced percentage change in metabolite abundance after glucose challenge.
For clarity, changes were truncated at 660%. Unmeasured nodes are shown in grey. Edges corresponding to different types of functional links between
metabolites are indicated. Cellular locations for metabolites in (a) are assumed to be extracellular unless denoted by [c] for cytoplasmic. Likewise, cellular
locations in (b) are assumed to be cytoplasmic unless denoted by [e] for extracellular. The lac-pyr-cit-akg group of metabolites in (a) is connected to the
remainder of the set via metabolites with relative frequencies,0.20 across solutions; the same is true of the bile salts cluster in (b).
doi:10.1371/journal.pcbi.1000692.g002
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corresponding reaction, involved in purine biosynthesis, gluta-
mine transfers an amine group to PRPP to form glutamate and
ribosylamine-5-phosphate. Ribosylamine-5-phosphate, in turn, is a
building block for de novo purine biosynthesis. Interestingly, many
of the other peripheral changed metabolites linked to PRPP in the
NGT-CMRN AMG are also involved in nucleotide biosynthesis.
Ribose-5-phosphate, which is interconverted with ribose-1-phos-
phate (R1P; the two cannot be distinguished on our mass
spectrometry platform), is phosphorylated to form PRPP. R1P
combines with xanthine (and hypoxanthine) as part of the purine
salvage pathway of nucleic acid biosynthesis, in a reaction
catalyzed by purine nucleotide phosphorylase (PNP). PNP also
catalyzes the reaction of nicotinamide with R1P to ultimately form
nicotinamide adenine dinucleotide (NAD). Thus the peripheral
metabolite cluster shown in NGT-CMRN captures the interrela-
tionship of the various metabolites involved in insulin-stimulated
purine nucleotide biosynthesis [26].
The other peripheral metabolite clusters in the NGT-CMRN
and NGT-EMRN AMGs capture other insulin-stimulated activ-
ities including glycolysis, triglyceride biosynthesis, and an increase
in bile salt plasma levels (by unknown mechanisms). Although
these were commented upon previously [10], we note that the bile
salts are linked by edges corresponding to common transporters
(see Figure 2, Table 1)–thus one mechanism not noted previously
by which glucose/insulin could increase plasma bile salt levels is
via increased transporter activity, with diffusion outwards along a
concentration gradient.
A Role for the Osmoregulatory Transporter SLC6A12 in
the Glucose Response
For the NGT group, there is a significant drop in L-Proline and
N,N-dimethylglycine levels and an increase in glycine betaine levels.
All three amino acids appear in the NGT-EMRN and NGT-
CMRN AMGs with the edges between them representing shared
transport by the SLC6A12 carrier [27] (Figure 2). SLC6A12 is an
ancient, highly-conserved osmoregulator, which controls cellular
volume by regulating extrusion of the osmolytes GABA and glycine
betaine when placed in solutions of varying osmolarity [28].
SLC6A12 can also transport proline, diaminobuytric acid, and
beta-alanine, and to a lesser extent glycine, putrescine, dimethyl-
glycine and choline [29]. Interestingly, from the CMRN we see that
glycine betaine and dimethyl glycine are also reactants and products
in a metabolic reaction (catalyzed by betaine-homocysteine
methyltransferase), which involves a reversible transfer of a methyl
group from betaine to homocysteine, resulting in methionine and
dimethylglycine (Figure 3). Insulin-triggered amino acid influx
Table 1. Enrichment for enzymes and transporters in the NGT and IGT active module groups.
Enzyme or
Transporter Family
Enzyme or Transporter
Family Member System
Measured Substrates in Active
Module Groups Reaction Tissue Distribution
SLC6 SLC6A14* B(0,+) Citr-L, Leu-L, Ile-L, Met-L, Lys-L, Val-L, Phe-L,
Tyr-L, Trp-L, His-L, Orn-L, Ser-L, (reduced
transport for Thr-L, Hom-L, Asn-L, Gln-L)
Facilitated lung, trachea, salivary gland,
mammary gland, pituitary,
stomach, colon
SLC6 SLC6A15{ NA Val-L, Leu-L, Met-L, Ile-L Facilitated brain
SLC6 SLC6A19* B(0) Citr-L, Leu-L, Ile-L, Phe-L, Trp-L, Tyr-L, Gln-L,
Met-L, Asn-L, Hom-L, Thr-L, Ser-L
Facilitated kidney, intestine
SLC3/SLC7 SLC7A1{ y+ Lys-L, Arg-L, Orn-L, His-L Facilitated Ubiquitous except liver
SLC3/SLC7 SLC7A2{ y+ Lys-L, Arg-L, Orn-L, His-L Facilitated liver, skeletal muscle,
pancreas
SLC3/SLC7 SLC7A3{ y+ Lys-L, Arg-L, Orn-L, His-L Facilitated thymus, overy, testis, brain
SLC3/SLC7 SLC3A2/SLC7A5* L Tyr-L, Phe-L, Trp-L, Leu-L, Ile-L, Val-L, His-L,
Citr-L
Exchange brain, ovary, testis, placenta
SLC3/SLC7 SLC3A2/SLC7A8{ L Citr-L, Gln-L, Leu-L, Ile-L, Met-L, Val-L, Phe-L,
Thr-L, Asn-L, Trp-L, Ser-L, Tyr-L, Hom-L
Exchange kidney, intestine, brain,
placenta, ovary, testis,
muscle, epithelium
SLC3/SLC7 SLC3A1/SLC7A9* b(0,+) Lys-L, Val-L, Orn-L, Met-L, Ile-L, Leu-L Exchange kidney, intestine, lung,
placenta, brain, liver,
endothelium
SLC43 SLC43A1* L Val-L, Ile-L, Citr-L, Leu-L, Phe-L, Met-L Facilitated kidney
SLC43 SLC43A2* L Val-L, Ile-L, Citr-L, Leu-L, Phe-L, Met-L Facilitated kidney
SLC38 SLC38A4{ A Met-L, Lys-L, His-L, Arg-L, Asn-L, Ser-L Facilitated liver, skeletal muscle,
kidney, pancreas
SLCO1 SLCO1A2{ NA taurochenodeoxycholate, glycocholate,
glycochenodeoxycholate
Facilitated brain, kidney, liver, ciliary
body
SLCO1 SLCO1B1{ NA taurochenodeoxycholate, glycocholate,
glycochenodeoxycholate
Facilitated liver
SLCO1 SLCO1B3{ NA taurochenodeoxycholate, glycocholate,
glycochenodeoxycholate
Facilitated liver
The FuncAssociate program [14] was used to identify enzymes and transporters that contributed a greater number of metabolites to the AMGs than expected by
chance. Amino acid transporters with substrate profiles overlapping AMG metabolites organized in groups, with the transport system, AMG. substrates and mode of
reaction (facilitated diffusion vs. exchange) and tissue distribution are indicated [22].
*Transporters/enzymes with padj,0.0125 (p,0.05 with Bonferonni correction for 4 AMGs experiments tested for enrichment).
{transporters with padj= 0.0125–0.05.
doi:10.1371/journal.pcbi.1000692.t001
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could, in fact, be coupled to glycine betaine extrusion since
methionine influx would tend to drive the betaine-homocysteine
reaction in reverse, leading to depletion of cellular dimethylglycine
and increased glycine betaine. The latter twometabolites could then
follow their respective concentration gradients resulting in betaine
export and dimethylglycine import, explaining the respective
increase and decrease in plasma levels. Presumably, the purpose
of this coupling is to maintain cell osmolarity in face of the amino
acid/glucose influx brought about by insulin.
Comparison of NGT and IGT Active Modules
The IGT-EMRN and IGT-CMRN (Figure S1) consist
exclusively of a group of amino acids with decreased plasma level
upon glucose load. Neither includes the SLC6A12 substrates, bile
salts, and citric acid cycle metabolites, glycerol or glycerol-3-
phosphate, or the purine nucleotide metabolism substrates. Thus,
the glucose- and/or insulin-stimulated changes in the correspond-
ing enzyme or transporter activities appear to have been blunted
in the IGT group.
Changed Metabolites Cluster According to Transporter
Activity
Although the AMGs convincingly illustrate that changed
metabolites are common substrates of small molecule transporters,
they cannot establish coordinated activity of these cotransported
substrates. To explore whether metabolite substrates of individual
transporters are in fact coregulated, we performed hierarchical
clustering across the 25 individuals from the NGT and IGT
groups, looking to identify metabolites that show a similar absolute
percentage of change across individuals.
Heatmaps of the results of hierarchical clustering (Figure 4,5)
demonstrate that amino acids naturally group by transporter
activity. For example, Clusters III and IV in NGT and IGT
correspond to the activities of the System A and System L amino
acid transporters, respectively. The System L transport activity is
responsible for transporting large hydrophobic and aromatic
amino acids with a particular preference for Phe, Leu/Ile
(indistinguishable on our platform), Met, and Val. The corre-
sponding peak intensities of these 4(+1) amino acids cluster
tightly together across individuals (Spearman correlation coeffi-
cient 0.35–0.85 for NGT; 0.39–0.67 for IGT). Although Tyr and
Trp show weaker correlation with the remaining system L amino
acids, the clustering algorithm also groups them together in cluster
IV. Likewise, 7 of the 10 (IGT) and 7 of the 12 (NGT) possible
system A transport substrates, which are primarily small, neutral
amino acids, are grouped into cluster III. The basic amino acids,
which can be transported by System y+L (via exchange for the
large hydrophobic amino acids), System A or System ATB,0+
carriers, show the most variability in terms of cluster membership.
Cluster II in NGT includes all 3 of the measured SLC6A12
substrates (proline, glycine betaine and dimethylglycine), which
demonstrate absolute pairwise correlation coefficients ranging
from 0.23 (for dimethylglycine and glycine betaine) to 0.57 (for
glycine betaine and proline). Proline and glycine betaine also are
strongly correlated and co-cluster in IGT (Spearman correlation
coefficient = 0.60). The proline-betaine correlation likely reflects
the fact that these metabolites are cotransported by at least three
carriers (SLC6A12, SLC6A20 and SLC36A2). By contrast, these
two metabolites are not known to participate in any common
metabolic pathways, supporting the hypothesis that coordination
of measured plasma levels of proline and glycine betaine is via
regulation of their common transporters.
In Cluster I, bile salts are found with citrulline in both NGT and
IGT. In IGT, malate also clusters closely with citrulline. We
searched PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) to
find a connection between these metabolites and, interestingly,
found that deficiency in the hepatic splice variant of the SLC25A13
protein (citrin), a component of the mitochondrial aspartate-malate
shuttle involved in liver NAD+/NADH shuttling, leads to a buildup
of both hepatic bile salts and citrulline [30]. SLC25A13 deficiency,
caused by a large number of possible mutations, underlies two
recessive Mendelian metabolic diseases: neonatal intrahepatic
cholestasis (NICCD) characterized by liver bile salt accumulation
and elevated citrulline plasma levels in infants and Type II
Citrullinemia (CTLN2), which is characterized by elevated
citrulline plasma levels in adults [31]. The widespread metabolic
defects in the two diseases arise from a lack of cytoplasmic aspartate
in the liver, an organ inherently limited in its ability to take up
aspartate from plasma. Hepatic aspartate deficiency in turn leads to
abnormalities in gluconeogenesis, ureagenesis, glycolysis, nucleotide
Figure 3. Proposed mechanism for coupling of methionine influx to SLC6A12 transport of glycine betaine and dimethylglycine for
osmoregulation. The connections among the 3 metabolites (and proline) in the NGT-EMRN and NGT-CMRN AMGs are shown, along with the Recon
1 betaine-homocysteine methyltransferase catalyzed reaction.
doi:10.1371/journal.pcbi.1000692.g003
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biosynthesis, and triglyceride biosynthesis either because of the
need for aspartate as a reactant or due to the resulting imbalance in
the cytoplasmic NAD+/NADH ratio. Interestingly, an examination
of Cluster I in NGT and IGT reveals that a large majority of
changed metabolites correspond to pathways known to be regulated
by liver aspartate levels and/or show abnormalities in SLC25A13
deficiency [32,33]. These include pyrimidine biosynthesis (OMP,
ribose-1-phosphate), purine biosynthesis (ribose-1-phosphate, xan-
thine, hypoxanthine, xanthosine), triglyceride biosynthesis (glycerol,
glycerol-3-phosphate), urea cycle (citrulline, ornithine), bile salt
accumulation (taurochenodeoxycholate, glycocholate, glycocheno-
deoxycholate), glycolysis (lactate, pyruvate), malate shuttling (malate,
alpha-ketoglutarate), and aspartate biosynthesis (asparagine). The
levels of several of these metabolites are known to be abnormal in
affected humans and/or in mouse models of SLC25A13 deficiency
[33]. Furthermore, in CTLN2, the abnormalities in these pathways
are exacerbated by glucose intake [34], consistent with the observed
OGTT-induced changes in metabolite levels.
To further examine the relationship between distinct transport
activities in OGTT metabolite profiling, we analyzed change in
plasma levels of metabolites for NGT and IGT using principal
component analysis (PCA). This analytic technique attempts to find
linear combination of metabolites that best explain the interindi-
vidual variation seen in metabolite profiles. PCA revealed that the
Figure 4. Hierarchical clustering of changed metabolites (FDR,0.05) in NGT Group. Grouping is according to 12|r|, where r is the
Spearman correlation coefficient for percentage change in metabolite abundance. Metabolite clusters that correspond to established transporter
activities are highlighted. Cluster I corresponds to the SLC25A13 transporter (liver variant); Cluster II corresponds to SLC6A12; Cluster III corresponds
to the small aliphatic system A transport system (SLC6, SLC7 and SLC38 transporters); and cluster IV corresponds to the hydrophobic/aliphatic system
L transport system (SLC6, SLC7, SLC43).
doi:10.1371/journal.pcbi.1000692.g004
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top two eigenvectors for NGT coincided with SLC25A13 and
amino acid transport activities, respectively, explaining a total of
39% of interindividual variance in metabolite changes (see Figure 6).
The discovery of orthogonal axes of variation corresponding to
these known transport activities supports the importance of
metabolite transport in OGTT profiles. The demarcation between
the two types of transport was not as well seen for the top two IGT
eigenvectors, which may reflect the significant heterogeneity in
insulin resistance across the IGT group.
Metabolite Transporters are Involved in Human Diseases
Given that metabolite profiling of perturbation experiments can
interrogate specific underlying transporter activities, we investi-
gated to what extent transporters are involved in human disease.
We consulted the OMIM database of Mendelian diseases (http://
www.ncbi.nlm.nih.gov/omim), and found 179 human disease
phenotypes associated with transporter mutations. These include
some of the transporters whose activity is reflected in OGTT
metabolite profiles, such as SLC25A13, described above. In addition,
the SLC6A14 amino acid/acyl-carnitine transporter, which primarily
carries large hydrophobic and cationic amino acids, was both
identified in our analysis as relevant to OGTT and previously been
found to be associated with metabolic disease. Mutations in
SLC6A14 have been shown to be associated with obesity in three
independent populations [35,36] and multiple SLC6A14 SNPs are
suggestively associated (nominal p-value,1024–1025) with waist
circumference and weight in type 2 diabetes patients studied in the
Diabetes Genomics Initiative genome-wide association study [37,38].
Figure 5. Hierarchical clustering of changed metabolites (FDR,0.05) in IGT Group. Grouping is according to 12|r|, where r is the
Spearman correlation coefficient for percentage change in metabolite abundance. Metabolite clusters that correspond to established transporter
activities are highlighted. Cluster numbering is as in Figure 4.
doi:10.1371/journal.pcbi.1000692.g005
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Figure 6. Principal component analysis of significantly changedmetabolites (FDR,0.05) in NGT and IGT. Panels (a) and (b) correspond to
NGT and IGT, respectively. Principal component #1 largely corresponds to pathways regulated by hepatic SLC25A13 activity, including glycolysis (lac,
pyr) and gluconeogenesis (ala, ser), nucleotide biosynthesis (OMP, r1p, hxan, xan, xtsn, ncam), bile salt (gchol, tdchol) and citrulline (citr) accumulation,
and NAD+/NADH balance by malate shuttling (glu, akg, mal). Principal component #2 largely corresponds to System A and L amino acid transport.
doi:10.1371/journal.pcbi.1000692.g006
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Interestingly, a recent analysis of fasting metabolic profiles in obese,
insulin-resistant patients revealed that a metabolic signature
consisting of acyl-carnitine and branched chain and aromatic amino
acids was highly correlated with obesity and insulin-resistance [39].
Although the authors attributed the relationship to dietary branch
chain amino acid intake, we note the overlap with our glucose-
stimulated System L transport cluster and with NGT principal
component #2. Our results highlighting the importance of
transporters in plasma metabolite profiles suggest that this signature
may in part reflect basal insulin-responsive amino acid transporter
activity.
Limitations
Given that we have measured plasma levels for only a small
fraction of the human metabolome, the pathway models that we
have discovered may be smaller than the actual enriched pathway.
Conversely, for those AMGs that include unmeasured metabolites,
measurement of additional metabolites may show that other
pathways more convincingly explain the observed physiological
changes. A further limitation is that our scoring method
considered all significant changes in plasma levels equivalently,
without considering direction of change. Additionally, we expect
there are alterations in metabolic reaction flux within the cell in
response to glucose challenge that may be difficult to decipher
from plasma metabolite levels. Finally, metabolites that are
significantly changed but which are not closely linked to other
metabolites via chemical reactions or shared enzymes/transporters
are unlikely to appear in AMGs, but may still reflect important
altered tissue activities during OGTT.
Discussion
We have directly integrated metabolic reaction connectivity and
a collection of shared transporter relationships, extended here by
manual literature curation, into metabolite profile interpretation to
identify biologic processes relevant to a physiological perturbation
experiment. Our approach makes use of a deterministic approach
to identify active modules and directly integrates plasma
measurements of metabolites with a unipartite graph capturing
interrelationship between metabolic substrates. Through this
method, we have uncovered a potentially important contribution
for transporter activities in plasma metabolite profiles, which is
ignored by using more traditional analysis of metabolic pathways.
A prior application of active modules to metabolism relied on
integrating microarray-derived gene expression information for
enzymes with enzyme connectivity in metabolic graphs to identify
clusters of functionally connected enzymes that collectively show a
high degree of change in a perturbation experiment [18]. In the
same study, ‘‘reporter metabolites’’ were identified by connection
to enzymes that show a high degree of change at a transcriptional
level. Our method allows deriving potentially unexpected
underlying pathways from direct metabolite measurements, which
should prove increasingly valuable given the emergence of
metabolic profiling in both biological and clinical arenas [40].
One motivation for this approach is to redefine human disease
in terms of aberrant metabolic activities. Given groups of affected
and control individuals, active module analysis can achieve this
in a number of ways. Baseline differences in each metabolite’s
abundance can be scored between affected and unaffected
individuals [39] and interpreted in the context of a metabolic
reaction network. As opposed to the lists of significantly changed
biomarkers commonly generated in association analyses, the data
integration involved in active module analysis allows hypotheses
generation in terms of more meaningful biological activities. As an
alternative to baseline comparisons, perturbation experiments
such as OGTT (or medication or exercise) can identify physiologic
pathways associated with the perturbation by identifying active
modules within the control group. In this way, analysis of
differences between affected and control individuals can be more
tightly focused on metabolites relevant to the normal physiological
process. Our study used this approach to suggest differences in
particular transporter and enzyme activities between the NGT and
IGT groups in response to glucose challenge. Using a perturbation
experiment, differences in the induced change in metabolite
abundance between affected and unaffected patients can also be
scored directly and mapped onto a metabolic reaction graph to
identify differentially active modules. Such modules may capture
distinct facets of a heterogeneous disease. Finally, longitudinal data
for a group of affected individuals permits subclassification of
disease via active module-based metabolite scores that measure the
ability to predict some adverse outcome (for example heart attacks
in individuals with stable coronary artery disease or diabetes
development in individuals with impaired glucose tolerance). A
similar approach used gene expression profiles [8] in the context of
a protein-protein interaction network to predict the likelihood of
cancer metastasis within individuals with breast cancer.
As the relationship of metabolite abundance with disease
incidence and outcomes is better understood, we may ultimately
be able to use integrated analyses of metabolic profiles to
subclassify disease on the basis of distinct enzymatic/transporter
activities, thus allowing a more individualized approach to clinical
medicine.
Methods
Physiologic Perturbation Experiments
Metabolite abundance measurements from an oral glucose
tolerance test have been described [10]. Briefly, 50 individuals
from the Framingham Offspring Study, 25 with normal fasting
glucose and normal glucose tolerance (OGTT-NGT) and 25 with
impaired glucose tolerance (OGTT-IGT) were selected for
metabolic profiling. The Framingham Heart Study is a longitu-
dinal community-based investigation that was initiated in 1948 to
prospectively identify cardiovascular disease risk factors [41]. The
children and their spouses of the original cohort were recruited in
1971 and constitute the Framingham Offspring Study Cohort. All
subjects were white and of European descent. OGTT was
administered routinely at the baseline exam. After a 12-hour
overnight fast participants were given 75 g glucose in solution
orally. Blood samples were drawn fasting and 120 minutes after
glucose ingestion and after HPLC purification, metabolite
abundances were determined using a triple quadrupole mass
spectrometer as previously described [10].
Mass Spectrometry Analysis
Metabolite peak intensities were determined as described
previously [10]. We eliminated metabolites from subsequent
analysis that: 1) were not included in the Recon 1 network; 2) were
confounded by a potential contaminant; or 3) were measured in
,50% of individuals In cases where two or more metabolites could
not be separated on the basis of chromatographic elution patterns
and parent and daughter mass-to-charge ion spectra, peak
intensities for that group of metabolites were randomly assigned
to one of the possible metabolites during each of the 100 simulations
(see below). This ambiguity was only present for 3 groups of
metabolites (leucine/isoleucine; ribose-5-phosphate/ribose-1-phos-
phate/ribulose-5-phosphate, citrate/isocitrate), with members of
each group showing chemical similarity and participating in many
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common reactions in Recon 1. By these criteria, the initial list of 171
peaks measured on the platform was thus narrowed to abundances
for 88 and 84 metabolites, respectively, for the NGT and IGT
groups. A one-sample Wilcoxon signed rank test was used to
determine the statistical significance for change for the metabolite
peak intensities for both groups (percent difference in peak
magnitude after glucose challenge relative to baseline).
Signal-Noise Decompositon
In order to identify significantly changed clusters of functionally
connected metabolites, we converted experimental p-values from
the Wilcoxon test to scores. Although a variety of methods can be
selected for this purpose, we used the beta-uniform distribution
method [12,42], which allows control of false-positive and false-
negative rates in the analysis. For NGT and IGT separately, the
distribution of p-values was modeled as a mixture of a beta
distribution for the signal and a uniform distribution for the noise as
shown below:
f x a,pjð Þ~pz 1{pð Þaxa{1 ð1Þ
where x is a given p-value, f(x) is the probability density at x, p
represents the mixture parameter, and a represents a shape
parameter for the beta distribution. The values of p and a were fit
using the optim function in R. The parameter t was chosen to
achieve an FDR of 0.01. p-values were converted into scores as
described in [12,42], where the score for each metabolite at the
chosen FDR, SFDR(x), is computed as follows:
SFDR xð Þ~ log ax
a{1
ata{1
 
~ a{1ð Þ log xð Þ{ log tFDRð Þð Þ ð2Þ
Using this statistic, nodes for which the p-value.t, will have a
negative score.
Construction of Metabolic Reaction Network
A Metabolic Reaction Network (MRN) was constructed based
on the 3338 metabolic reactions in Recon 1. We treated all 1500
reactant and product metabolites in Recon 1 as nodes. Cellular
locations were assigned to each metabolite as specified in Recon 1,
and metabolites were split into multiple nodes (each corresponding
to a different location). This process resulted in 2779 total nodes.
For each metabolic reaction, edges in the MRN were drawn
between each reactant and product nodes and between all common
metabolites substrates (reactants and products) of enzymes and
transporters. Furthermore, since transporter annotation was not
complete, for each of the measured metabolites we manually
searched the literature to identify transporter-substrate relationships
and identified all substrates for any transporter found. Finally, we
expanded the list of reactions so that each transporter-reaction
relationship was reflected in an independent entry. This approach
resulted in an additional 737 reactions (see Table S2).
To improve the specificity of the active module discovery
process, nodes and edges involving the following 28 ‘promiscuous’
and/or buffered metabolites were also eliminated: UMP, UDP,
UTP, FAD, FADH2, Na
+, K+, SO4, NH4, CO2, Phosphate, O2,
Pyrophosphate, H2O, H
+, OH2, ATP, ADP, AMP, CTP, CDP,
CMP, NAD, NADH, NADP, NADPH, H2O2, and HCO3
2. As
many of these metabolites serve as cofactors, their inclusion would
contribute to non-specific bridges between metabolites in active
modules and would thus be of limited use for biological processes.
We did however include nodes and edges for reactions where
nucleotides serve as primary reactants and products, such as those
involved in nucleotide biosynthesis or catabolism; NAD metabo-
lism; and Riboflavin metabolism.
Because abundance measurements were only available for a small
fraction of the metabolic network, we limited the MRN to the union
of measured metabolites and all nodes found on paths (up to path-
length three) between two measured nodes. This filtering, used to
reduce computing cost, did not alter downstream results because to
be included in an active module, a metabolite must either be
measured or lie on a path between measured metabolites.
Scores generated above were assigned to measured nodes in the
MRN. We built both a Scored Extracellular MRN (EMRN) and a
separate Scored Cytoplasmic MRN (CMRN). For the EMRN, if a
metabolite had two cellular locations, the metabolite score was
assigned to the extracellular metabolite, modeling extracellular
levels; for the CMRN, scores, in such a situation, were assigned to
the cytoplasmic metabolite. The EMRN and CMRN networks
had 297 nodes and 5515 edges and 344 nodes and 6089 edges,
respectively, after applying the above steps.
Determination of Active Subnetworks
To identify active modules in our MRN, we used a recently
developed method [12] that provides an exact solution to the
problem of finding a group of connected nodes with the highest
combined score by transforming the problem to that of the Prize-
Collecting Steiner Tree. The method requires that each
metabolite in the network have a score (see above for details on
the required properties of that score). Because we had scores
assigned for only a fraction of the network nodes, p-values for
unmeasured nodes were sampled randomly from the uniform
distribution expected of unchanged metabolites, thus sampling the
joint distribution of unmeasured metabolite abundance under the
null hypothesis. Such an approach is common practice in Bayesian
data analysis to estimate posterior probability distributions and
accounts for our uncertainty about unmeasured metabolites more
accurately than would asserting that we are sure that the
metabolite has not changed. It also permits an unmeasured
metabolite to be included in a cluster if there is sufficient support,
in that the unmeasured metabolite bridges multiple high-scoring
measured metabolites. Scores were then determined for the
unmeasured nodes as described in Methods, with p, a, and t
determined using the distribution of measured p-values. We
repeated the random sampling 100 times for each scored network
and identified one optimal solution per network. We explored
searching also for suboptimal solutions but found that these
primarily consisted of a subset of the metabolites of the optimal
solution rather than other distinct areas of the graph.
Statistical Significance of Active Subnetwork Solutions
For the purpose of evaluating statistical significance of observed
active modules, we generated random solutions by repeating the
active module discovery process for 100 random scored MRNs.
Although the topology was preserved, the scores for each random
MRN were randomly permuted among measured nodes and
p-values for unmeasured nodes were sampled uniformly at
random. The distribution of scores for the original and permuted
data were compared by a one-sided Mann-Whitney-Wilcoxon test
using the R package (www.Rproject.org).
Predefined Pathway and Enzyme/Transporter Enrichment
of Active Module Clusters
For each scored MRN, the frequency of appearance in the
corresponding 100 solutions was measured for all nodes. Nodes
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with $0.20 relative frequency were grouped together to form an
Active Module Group (AMG), which was examined for significant
overlap with metabolite sets corresponding to predefined path-
ways. To identify predefined pathway enrichment in the AMGs,
we used a modified version of the FuncAssociate program [14].
FuncAssociate takes as input a query list of metabolites and a
mapping of pathways to metabolites. For each pathway, it tests for
enrichment of that pathway in the query list relative to the ‘‘tested
universe’’ of metabolites by using the cumulative hypergeometric
(Fisher’s Exact) test. Adjustment for multiple hypothesis testing
is achieved by resampling [14]. Briefly, the null distribution of
p-values is generated by repeating the test for 1000 randomly
generated query lists of the same size from the same universe of
metabolites. For each random query list, the minimum p-value
observed for any pathway is retained. The adjusted p-value (padj) is
then the fraction of random query lists that yield a minimum
p-value equal to or lower than the minimum p-value observed.
We generated pathway and enzyme/transporter-to-metabolite
mappings for Recon 1, limiting our analysis to pathways, enzymes
or transporters that included at least three metabolites in the
metabolite universe. We were interested in enrichment for
analysis for both AMGs and for our ranked list of changed
metabolite. To look for pathway enrichment in the ranked list of
changed metabolites, we used the ‘‘ordered’’ setting in FuncAs-
sociate (http://llama.med.harvard.edu/cgi/func1/ funcassociate_
advanced), which tests a ranked list of metabolites and finds the
rank cutoff that optimizes significance (using resampling to adjust
for multiple testing). For this analysis, the metabolite list was
ranked in both increasing and decreasing order of magnitude of
change.
For assessing pathway and enzyme/transporter enrichment in
our AMGs, we used as our universe of metabolites all nodes in the
reduced networks. To address the fact that the AMGs may be
biased in composition towards measured nodes, we modified
FuncAssociate so that the null distribution of p-values was obtained
using randomly generated metabolite lists that matched the
query list in composition of measured and unmeasured nodes.
We repeated the same process for enzymes and transporters,
generating mappings for all Recon 1 reactions for which an
enzyme or transporter could be identified.
Tissue of Origin Enrichment of Active Module Clusters
In a recent manuscript [19], tissue-specific metabolic fluxes
were predicted for the Recon 1 network. The authors solved a
constraint-based modeling optimization problem by finding a
metabolic flux distribution that satisfied constraints imposed by
stoichiometric and thermodynamic conditions of the network and
maximized agreement between flux and enzyme mRNA and
protein expression for ten human tissues. We used the authors’
predictions for metabolite activity in each of the ten tissues and
looked for tissue enrichment for our measured metabolites and
active modules clusters. For each metabolite and cellular location
within each tissue, the authors provided an activity score that
ranged from 22 to +2, where positive scores indicated activity,
negative scored indicated inactivity and the magnitude of the score
indicated confidence in the prediction. A score of 0 indicated an
ambiguous activity level. For each AMG, we computed an activity
score for each tissue by summing the individual scores for each
metabolite. The null distribution of scores was obtained as above,
where 1000 random sets of metabolites were selected from the
node universe, matching the AMG in composition of measured
and unmeasured nodes, and the highest tissue score taken for
each set.
False Discovery Rate, Hierarchical Clustering and
Principal Component Analysis of Changed Metabolites
Hierarchical clustering and PCA was performed on the subset
of metabolites that changed significantly in either NGT or IGT at
an FDR,0.05, determined using the qvalue package in R (www.
Rproject.org). L-Alanine and L-Cysteine, which were the only
measured standard amino acids that failed to change significantly
in either group, were also included. Input data corresponded to
fractional change in metabolite abundance across individuals. For
clustering, the absolute value of the Spearman coefficient was used
to compute the dissimilarity matrix. Heatmaps and principal
component analyses were performed using the heatmap and prcomp
functions, respectively, in the R package.
Sensitivity of Active Module Results to Alterations in
Parameter Values/Thresholds
In our analysis, three parameters determined the balance
between measured and unmeasured metabolites in our active
module solutions: 1) the false-discovery rate (FDR) threshold used
in the determination of scores for measured metabolites; 2) the
path-length threshold between measured metabolites used in
filtering unmeasured metabolites from the MRN; and 3) the
frequency threshold used in selecting active module solution
metabolites for inclusion into active module groups. Although
unmeasured metabolites are useful for hypothesis generation in
terms of identifying potentially novel markers of insulin function,
such hypotheses should not be so numerous as to dominate the
analysis. At the stringent FDR of 0.01 selected, the active module
discovery process was relatively insensitive to changes in the other
two parameters, with little difference in the observed results at
higher or lower path lengths. In fact, all unmeasured metabolites
in active module groups were directly connected to one or more
measured metabolites. For the frequency cutoff for active module
group metabolites, our primary conclusions were robust to all
thresholds from 0.10 to 0.50.
Supporting Information
Table S1 Metabolite profiles for NGT and IGT groups. Recon
1 symbols and names for measured metabolites are listed alongside
magnitude (fraction of baseline) and significance (p-value) of
change in abundance after glucose challenge. Metabolite abun-
dances pre- and post- glucose challenge are also provided in
separate tabs for the NGT and IGT groups.
Found at: doi:10.1371/journal.pcbi.1000692.s001 (0.13 MB XLS)
Table S2 Manually curated transport reactions used in addition
to Recon 1 reactions to derive Metabolite Reaction networks. The
first tab corresponds to 190 reactions already described in Recon 1
- a column was added that makes explicit the mapping to a single
solute transporter. The second tab corresponds to 737 additional
transport reactions identified by manual literature curation - these
have also each been mapped to a single transporter.
Found at: doi:10.1371/journal.pcbi.1000692.s002 (0.22 MB XLS)
Table S3 Relative frequencies for metabolites in Active Module
Solutions. A frequency threshold of 0.20 for appearance of
metabolites was used for subsequent analysis and figure construction.
Found at: doi:10.1371/journal.pcbi.1000692.s003 (0.07 MB XLS)
Table S4 Metabolic reactions and/or enzymes/transporters
corresponding to edges in AMGs. Edges correspond to reactant-
product pairs in individual reactions and/or substrates of common
enzymes/transporters.
Found at: doi:10.1371/journal.pcbi.1000692.s004 (0.12 MB XLS)
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Figure S1 Active Module Group from a) IGT-EMRN and b)
IGT-CMRN. For details see legend for Figure 2.
Found at: doi:10.1371/journal.pcbi.1000692.s005 (0.46 MB EPS)
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